Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL124467 | 0.81 | MEN1 (0.46) | KDM4EHPGDHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL21827176 | 0.78 | KDM4E (0.41) | KDM4EHPGDHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL28352403 | 0.76 | P2RX3 (0.49) | KDM4EHPGDALDH1A1SMN1; SMN2HSP90B1 | |
| SCHEMBL29528921 | 0.76 | P2RX3 (0.49) | KDM4EHPGDALDH1A1SMN1; SMN2HSP90B1 | |
| SCHEMBL31168612 | 0.74 | KDM4E (0.41) | KDM4EHPGDHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL31168603 | 0.73 | AGBL2 (0.42) | KDM4ECA12CA2CA7CA9 | |
| SCHEMBL31168685 | 0.73 | EGFR (0.48) | KDM4EHPGDHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL28352405 | 0.71 | P2RX3 (0.55) | KDM4EHPGDALDH1A1SMN1; SMN2HSP90B1 | |
| SCHEMBL21827960 | 0.70 | LMNA (0.38) | KDM4EHPGDHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL8825478 | 0.69 | ALDH1A1 (0.53) | KDM4ECA12CA1CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273761-B2 | Tricyclic compound and medical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273761-B2 | Tricyclic compound and medical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273761-B2 | Tricyclic compound and medical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2100895-B1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-03-07 | — | — | EP | disclosed |
| EP-2100895-B1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100029707-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029707-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029707-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2100895-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-09-16 | — | — | EP | disclosed |
| EP-2100895-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029707-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | MTNR1A, MTNR1B, AHR | KDM4E 1150/4885CA12 1263/4885CA1 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.